Cov19VaxKB: COVID-19 Vaccine Knowledgebase

COVID-19 Vaccine News

This site provides a list of recent COVID-19 vaccine news updates.

7/30/2022: U.S. government reaches deal with Moderna for updated Omicron COVID-19 vaccine
7/19/2022: CDC recommends Novavax’s COVID-19 Vaccine for adults
6/18/2022: CDC recommends COVID-19 vaccines for children between 6 months and 5 years of age
5/17/2022: FDA expands eligibility for Pfizer-BioNTech COVID-19 Vaccine booster dose to children 5 through 11 years
5/5/2022: FDA limits use of Janssen COVID-19 Vaccine to certain individuals
3/29/2022: FDA authorizes second booster dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines for older and immunocompromised individuals
1/31/2022: FDA approves the Moderna COVID-19 vaccine, marketed as Spikevax
1/3/2022: FDA authorizes COVID-19 vaccine boosters for children 12 to 15 years of age
12/20/2021: European Union authorizes Novavax's COVID-19 vaccine for use in people 18 years and older
12/16/2021: CDC panel recommends people not get J&J vaccine if Pfizer, Moderna available
11/19/2021: FDA authorizes COVID-19 booster shots for all adults
11/2/2021: Indonesia is first country to authorize Novavax Covid-19 vaccine
10/29/2021: FDA authorizes the Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
10/20/2021: Iran abandons FAKHRAVAC vaccine due to low demand
9/22/2021: FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations
8/23/2021: FDA approves the Pfizer-BioNTech COVID-19 vaccine, now marketed as Comirnaty
8/20/2021: India authorizes the COVID-19 DNA vaccine ZyCoV-D for emergency use
6/29/2021: Altimmune discontinues AdCOVID nasal spray development after disappointing Phase I trial results
6/22/2021: Cuba says Abdala vaccine 92.28% effective against coronavirus
6/14/2021: Iran authorizes the emergency use of the COVIran Barakat vaccine
6/9/2021: China authorizes Chinese Academy of Medical Sciences COVID-19 vaccine for emergency use
5/27/2021: WHO approves Sinovac COVID-19 vaccine for emergency use, enabling the vaccine to be used in the COVAX vaccine sharing program
5/27/2021: Sanofi and GSK initiate a Phase III trial of their recombinant COVID-19 vaccine
5/14/2021: Kangtai Biological's COVID-19 vaccine gets emergency use approval in China
5/13/2021: Cuba authorizes the Soberana 02 and Abdala vaccines for emergency public use
5/10/2021: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for 12-15 year olds
5/8/2021: WHO approves Sinopharm vaccine in potential boost to COVAX pipeline
5/6/2021: Russia authorises single-dose Sputnik Light COVID vaccine for use
4/23/2021: FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine following safety review
4/13/2021: FDA and CDC recommend a pause of the Johnson & Johnson vaccine following reports of rare blood clots in 6 people receiving the vaccine
4/1/2021: Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to 6 months following second dose in updated analysis of Phase III trial
3/31/2021: Pfizer and BioNTech announce positive topline results of COVID-19 vaccine study in adolescents aged 12-15 years old
3/24/2021: AstraZeneca says COVID-19 vaccine 76% effective in new analysis, to seek U.S. approval
3/18/2021: Germany, France among nations to resume use of AstraZeneca vaccine after regulators back shot
3/11/2021: Denmark, Norway and Iceland suspend AstraZeneca COVID shots after blood clot reports
3/1/2021: Uzbekistan approves ZF2001 vaccine developed by China’s Anhui Zhifei Longcom Biopharmaceutical
2/27/2021: FDA issues Emergency Use Authorization for Johnson & Johnson COVID-19 vaccine
2/17/2021: World's first coronavirus Human Challenge study receives ethics approval in the UK
2/7/2021: South Africa halts administration of the AstraZeneca COVID-19 vaccine after studies suggest the vaccine fails to provide immunity against the South African SARS-CoV-2 variant
2/6/2021: Sinovac Announces Phase III Results of Its COVID-19 Vaccine
2/5/2021: Latest monitoring data confirms safety of COVID-19 vaccines
2/2/2021: Russia's Sputnik V (Gam-COVID-Vac) vaccine 91.6% effective in late-stage trial
1/29/2021: Phase III trial results of Johnson & Johnson's single-shot vaccine indicate 66% efficacy in preventing moderate to severe COVID-19
1/28/2021: Phase III trial results of Novavax's vaccine demonstrate 89% efficacy
1/27/2021: In vitro studies demonstrate Pfizer and BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with key mutations present in U.K. and South African variants
1/22/2021: New research in Israel suggests that widespread COVID-19 vaccination can help prevent infection
1/6/2021: Serum Institute of India obtains emergency use authorisation in India for AstraZeneca’s COVID-19 vaccine
12/31/2020: China approves BBIBP-CorV vaccine for general use
12/30/2020: AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK
12/23/2020: Canada authorizes Moderna's COVID-19 vaccine
12/21/2020: The European Union authorizes Pfizer and BioNTech's COVID-19 vaccine
12/18/2020: FDA approves Moderna's COVID-19 vaccine for Emergency Use Authorization
12/13/2020: Bahrain's National Health Regulatory Authority approves Sinopharm COVID-19 vaccine
12/11/2020: FDA issues Emergency Use Authorization for Pfizer/BioNTech's COVID-19 vaccine
12/11/2020: AstraZeneca will test using component of Russia's Sputnik V in clinical trials of its own COVID-19 vaccine.
12/11/2020: Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
12/11/2020: University of Queensland and CSL announce that they will not proceed with Phase II and III clinical trials of their COVID-19 vaccine
12/9/2020: Canada approves Pfizer and BioNTech's COVID-19 vaccine, becoming the 2nd nation after the UK to approve a COVID-19 vaccine.
12/8/2020: UK begins administering the Pfizer/BioNTech COVID-19 vaccine to the public.
12/2/2020: UK regulator MHRA authorizes the supply and distribution of Pfizer and BioNTech's BNT162 vaccine, marking the first Emergency Use Authorization of a COVID-19 vaccine anywhere in the world.
11/23/2020: AstraZeneca announces that the Phase III clinical trial for its AZD1222 vaccine met its primary efficacy endpoint.
11/18/2020: Pfizer and BioNTech announce that their COVID-19 vaccine, BNT162b2, has met all primary efficacy endpoints, after concluding the final efficacy analysis of a Phase III trial.
11/16/2020: Moderna announces that its COVID-19 vaccine has achieved a 94.5% efficacy rate, according to a preliminary analysis of its Phase III trial.
11/11/2020: Phase 3 trial of Sinovac’s COVID-19 vaccine in Brazil resumes after brief pause due to suicide of a study subject
11/9/2020: COVID-19 vaccine from Pfizer and BioNTech reported to be strongly effective, as indicated by early data from a Phase III trial.
10/23/2020: Johnson & Johnson prepares to resume Phase 3 Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
10/23/2020: FDA authorizes restart of the US Phase III trial of the AZD1222 vaccine
10/21/2020: Volunteer in placebo group of AZD1222 Phase III trial in Brazil dies, trial continues
10/12/2020: Johnson & Johnson pauses Phase III trial of Ad26COVS1 vaccine
10/2/2020: Phase III trial of AZD1222 vaccine in Japan resumes after pause, following restart of trials in the UK, Brazil, South Africa, and India
9/28/2020: Phase II/III trial of INO-4800 vaccine placed on partial clinical hold due to FDA concerns
9/15/2020: Phase III trial of AZD1222 vaccine in Brazil and South Africa resumes after pause
9/12/2020: Phase III trial of AZD1222 vaccine in the UK resumes after pause
9/9/2020: Clinical trials of AZD1222 vaccine placed on hold in the UK, USA, Brazil, and South Africa due to “adverse event” in a clinical trial subject

Provenance: All data in Cov19VaxKB originates from manual curation of various resources.

Note: The page was updated on July 30, 2022. Please provide us with any new information that you believe would be useful if included on the website. Thank you.